Formycon AG

FYB.DEPhase 3

Formycon AG is a Germany-based, publicly traded biopharmaceutical company dedicated to the development of biosimilars and innovative biologics. Its core expertise lies in the complex process development, analytical characterization, and manufacturing of protein therapeutics, with a robust pipeline targeting high-value markets. The company's strategy combines in-house development of key assets with strategic collaborations, such as its partnership with Bioeq AG, to advance products through clinical development and commercialization. Formycon's focus on high-quality, cost-effective alternatives to originator biologics positions it within the growing global biosimilars market.

Market Cap

$347.8M

Employees

100-250

Focus

Biotech

FYB.DE · Stock Price

USD 17.0647.54 (-73.59%)

Historical price data

AI Company Overview

Technology Platform

Integrated platform for the development of biosimilars and next-generation biologics, encompassing process development, analytical characterization, formulation, and regulatory strategy for complex protein therapeutics.

Pipeline Snapshot

4 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
FYB203 2 mg (0.05 mL of 40 mg/mL)	Age-Related Macular Degeneration	Approved
FYB201 0.5 mg (0.05 mL of 10 mg/mL)	Age-Related Macular Degeneration	Approved
FYB206 + FYB206 + Keytruda	Non Small Cell Lung Cancer	Phase 3
FYB206 + Keytruda	Melanoma, Stage II	Phase 1

Funding History

Total raised: $105M

Debt$75MEuropean Investment BankJun 15, 2021

IPO$30MUndisclosedJul 10, 2015

Opportunities

Formycon's primary growth opportunity lies in the successful commercialization of its approved ranibizumab biosimilar (YESAFILI®) across Europe and potentially the US, providing its first major product revenue.

Further value can be unlocked through the approval and launch of its late-stage aflibercept and ustekinumab biosimilars, which target multi-billion dollar markets.

The company's proprietary pipeline (FB704A, FB101) offers long-term potential for higher-margin innovative products.

Risk Factors

Key risks include regulatory setbacks in obtaining marketing approval for its biosimilar candidates, particularly from the FDA.

The company faces intense commercial competition from both originator products and other biosimilars, which could pressure pricing and market share.

Formycon also remains dependent on the success of its strategic partnership with Bioeq/Polpharma for its most advanced assets.

Competitive Landscape

Formycon competes with large biopharma firms (e.g., Amgen, Novartis/Sandoz) and dedicated biosimilar companies (e.g., Samsung Bioepis, Celltrion) in the global biosimilars market. Its differentiation is based on a focused expertise in complex molecules like fusion proteins, a strategic partnership that provides development and manufacturing strength, and a targeted pipeline in high-value ophthalmology and immunology markets.